Medtronic (NYSE:MDT) Price Target Raised to $115.00

Medtronic (NYSE:MDT) had its target price increased by Argus from $105.00 to $115.00 in a research note issued to investors on Tuesday, MarketBeat.com reports. They currently have a buy rating on the medical technology company’s stock.

Other research analysts have also issued reports about the company. Royal Bank Of Canada lowered their price target on Medtronic from $105.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday, May 22nd. Truist Financial raised their price target on Medtronic from $92.00 to $96.00 and gave the company a “hold” rating in a report on Thursday, August 21st. Citigroup raised their price target on Medtronic from $99.00 to $101.00 and gave the company a “buy” rating in a report on Thursday, August 21st. UBS Group raised their price target on Medtronic from $94.00 to $95.00 and gave the company a “neutral” rating in a report on Wednesday, August 20th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Medtronic in a research note on Friday, July 11th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $102.14.

Medtronic Stock Down 0.1%

NYSE MDT opened at $91.97 on Tuesday. The stock has a market cap of $117.97 billion, a PE ratio of 25.34, a P/E/G ratio of 2.34 and a beta of 0.80. Medtronic has a fifty-two week low of $79.29 and a fifty-two week high of $96.25. The business has a 50 day moving average price of $90.18 and a two-hundred day moving average price of $88.07. The company has a quick ratio of 1.42, a current ratio of 2.01 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm had revenue of $8.58 billion for the quarter, compared to analysts’ expectations of $8.37 billion. During the same period last year, the business posted $1.23 earnings per share. The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, sell-side analysts predict that Medtronic will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 17th. Stockholders of record on Friday, September 26th will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.1%. Medtronic’s dividend payout ratio (DPR) is 78.24%.

Insider Buying and Selling at Medtronic

In other Medtronic news, Director William R. Jellison purchased 2,500 shares of the company’s stock in a transaction on Monday, August 25th. The shares were bought at an average cost of $92.37 per share, with a total value of $230,925.00. Following the transaction, the director directly owned 5,000 shares in the company, valued at approximately $461,850. This represents a 100.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Burkett Financial Services LLC grew its holdings in shares of Medtronic by 185.0% during the 1st quarter. Burkett Financial Services LLC now owns 285 shares of the medical technology company’s stock worth $26,000 after purchasing an additional 185 shares in the last quarter. 1248 Management LLC acquired a new stake in Medtronic in the 1st quarter valued at $26,000. Wood Tarver Financial Group LLC acquired a new stake in Medtronic in the 4th quarter valued at $27,000. Delos Wealth Advisors LLC acquired a new stake in Medtronic in the 2nd quarter valued at $27,000. Finally, Columbia River Financial Group LLC acquired a new stake in Medtronic in the 1st quarter valued at $28,000. 82.06% of the stock is owned by institutional investors.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.